Patients with rheumatoid arthritis serum soluble synergistic signaling molecules sPD-1, sPD-L1 and significance of measurement of the concentration
|Keywords||Rheumatoid Arthritis Collaborative signaling molecules sPD-1 sPD-L1|
Objective: Rheumatoid arthritis (RA) patients with serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) and the condition assessment of RA correlation between indicators to explore synergies soluble signaling molecules sPD-1, sPD-L1 in RA disease occurrence and development of meaning. Methods : RA patients with 60 cases , of which disease activity group and remission group of 30 cases , while the collection of serum collected clinical and laboratory data , including: the patient's gender, age , disease duration, pain score (VAS), duration of morning stiffness , tender joint count , swollen joint count , disease activity score (DAS28), rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (CCP), erythrocyte sedimentation rate (ESR), C- reactive protein (CRP), health Questionnaire Evaluation (HAQ). And 20 cases of healthy control group , serum was collected . Enzyme-linked immunosorbent assay (ELISA) was measured in serum of RA patients and healthy controls in sPD-1, sPD-L1 concentration and analyzed sPD-1, sPD-L1 with RA disease assess the correlation between indicators . Results : (1) RA patients sPD-1 at a concentration of 390.41 ± 106.08pg/ml, higher than the healthy control group 335.00 ± 87.47pg/ml, a statistically significant difference between the two (p lt; 0.05). (2) RA disease activity in patients with serum sPD-1 at a concentration of 417.34 ± 105.35pg/ml, remission group was 363.49 ± 101.47pg/ml, RA disease activity group sPD-1 concentrations above the remission group and the healthy control group , the difference was statistically significant (p lt; 0.05). (3) RA patients sPD-L1 concentration of 111.88 ± 35.59pg/ml, slightly higher than the healthy control group 107.43 ± 39.30pg/ml, but no statistically significant difference between the two (P gt; 0.05). (4) RA patients sPD-1 concentrations were positively correlated with the duration of morning stiffness (P lt; 0.05). (5) RA patients sPD-1 with sPD-L1 concentrations were positively correlated (p lt; 0.05). Conclusion : RA patients and healthy human body can be detected in a certain amount of sPD-1, sPD-L1. RA patients sPD-1 concentrations higher than healthy persons , RA patients with active serum sPD-1 concentrations above remission group, and sPD-1 concentrations were positively correlated with the duration of morning stiffness , suggesting sPD-1 may be related to the pathogenesis of RA .